Atrian Bakers’s bread Tritordeum, made with the new cereal Agrasys, nominated to the Carrefour Innovation Awards Blog Post

A new type of bread  produced by Atrian Bakers  and made with Tritordeum,  has been nominated for the 2015 Carrefour Innovation Awards. The new type of bread will be subjected to population vote until the 21st of June. Tritordeum cereal is the first man-made cereal without genetic modification suitable for human consumption. Developed in the late 70s by a group of scientists from the Institute for Sustainable Agriculture (IAS) of the Higher Council for Scientific Research (CSIC)), and after 30 years of research, Agrasys -a spin-off company based at the Barcelona Science Park, founded by researchers from the IAS and the industry, launched the new bread to the market in April 2013.

Ordesa saw turnover grow to €112.4 millions, up 4.7%, in 2014 Blog Post

Laboratorios Ordesa today announced its results for the 2014 year, which reveal a growing trend mainly due to increased sales, cutting structural costs, implementing more efficient sales policies and consolidating foreign markets the company had opened in previous years. Since 2007, the Ordesa Group has a R&D&i center at Barcelona Science Park, from where the company actively participates in clinical studies and national and international research projects in the areas of immunology and cognitive development. The elaboration of hydrolyzed cereals, liquid milk, or the launching of the first porridge with bifidus effect, and supplemented infant formulas are some of the results from these projects. 

Ordesa leads the Smartfoods project Blog Post

The Centre for the Development of Industrial Technology (CDTI) has granted the Smartfoods industrial research project for the development of smart food to a consortium of companies led by Ordesa from this R&D&i center at Parc Científic de Barcelona.The aim of this research is the design of foods and screening tests that will help reduce the risk of some of the most frequently occurring diseases that will cause 3 of every 4 deaths in 2020.

iMols, the Mind the Byte cloud platform for drug discovery, is now available free of charge Blog Post

Mind the Byte –based at the Parc Científic de Barcelona and specializing in the provision of services and solutions for computational drug discovery- has opened cloud platform for use by the scientific, academic and business community. iMols is the first cloud platform specifically designed for drug discovery using the SaaS (‘Software as a Service’) approach. Mols is a SaaS platform breaks the two main barriers faced by computational drug design: implementation costs – it eliminates investments in servers and software licensing- and the training of the team, as it is an easy-to-use and intuitive tool requiring very little training.

 

Iproteos closes the first ‘crowdfunding’ campaign of the Spanish biotech sector Blog Post

The biotech Iproteos -located at the Parc Cientific de Barcelona- has managed to successfully close an innovative funding campaign based on equity crowdfunding with the aim of raising € 100,000 for the development of a new drug to stop progression and reverse the cognitive deficits associated with schizophrenia: IPR019. The funds raised will allow the biotech -a spin-off from the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) – complete the preclinical non-regulatory stage of the compound to begin clinical trials in 2016.

 

La Fundació GAEM organitza la 5a edició de les jornades ‘Volem Saber’TO TRANSLATE >>> Blog Post

El proper dijous 2 d’octubre a les 17.00h se celebra la cinquena edició de les jornades de divulgació científiques. En aquesta ocasió el Parc Científic de Barcelona, serà el lloc que acollirà la reunió entre científics, investigadors, administració pública i pacients, per parlar dels avenços que s’estan duent a terme en el camp de la investigació biomèdica en Esclerosi Múltiple.

Discovery of why colon cancer metastasis always follows the same invasive pattern Blog Post

A team of scientists led by Roger Gomis, ICREA researcher and head of the Growth Control and Cancer Metastasis Group at the Institute for Research in Biomedicine (IRB Barcelona), has identified the genes that favour staggered colon cancer metastasis. Published on Sunday in the journal Nature Cell Biology (doi:10.1038/ncb2977), in addition to Gomis, the authors include Angel R. Nebreda, ICREA and BBVA Cancer Research Professor, and Eduard Batlle, ICREA Professor and head of the Colorectal Cancer Lab, both at IRB Barcelona.

Agrasys launches to the market the first newly created cereal in the world for human consumption Blog Post

Agrasys, a spin-off of the Spanish National Research Council (CSIC) located at the Barcelona Science Park, has launched to the market Tritordeum, the first newly created cereal marketed in the world for human consumption. The official presentation took place at Hotel Claris in Barcelona, with a welcome by members of Agrasys and the participation of master baker Josep A. Ribas, author of the Cruixent artisan breads bakery, and Chef Josep M. Freixa, presently head of the Tradició Freixa Restaurant (awarded with a Michelin star).